Humanin Evidence Guide
Evidence for Humanin is too preliminary to support a research protocol with confidence. Data comes primarily from cell and rodent models, with a handful of observational human studies showing inverse correlations between Humanin levels and metabolic disease - not interventional data. The mitochondrial protective mechanism is interesting, but there is no actionable human protocol. NAD+ precursors have far more human interventional data for anti-aging applications.
Our Take
Evidence for Humanin is too preliminary to support a research protocol with confidence. Data comes primarily from cell and rodent models, with a handful of observational human studies showing inverse correlations between Humanin levels and metabolic disease - not interventional data. The mitochondrial protective mechanism is interesting, but there is no actionable human protocol. NAD+ precursors have far more human interventional data for anti-aging applications.
- Best for
- Mitochondrial protective peptide mechanistic research, neuroprotection models (preclinical only)
- Evidence grade
- Level D
- Confidence
- Low
- Starting point
- No established human protocol
Benefits and Evidence
- Neuroprotection: Level D, mostly non-human evidence - Protects neurons from amyloid-beta, oxidative stress, and excitotoxicity in cell culture and animal models. Improved cognitive outcomes in Alzheimer mouse models.
- Cytoprotection and Anti-Apoptosis: Level D, mostly non-human evidence - Broadly cytoprotective across multiple cell types including neurons, cardiomyocytes, pancreatic beta cells, and endothelial cells through BAX inhibition and STAT3 activation.
- Metabolic Regulation: Level D, mostly non-human evidence - Improved insulin sensitivity and glucose tolerance in animal models of diabetes. Circulating levels correlate inversely with metabolic syndrome markers in observational human studies.
Side Effects and Warnings
- Very limited safety data
- No significant adverse effects reported in animal studies
- Potential for excessive anti-apoptotic signaling with chronic administration (theoretical concern for tumorigenesis)
- Preclinical research only - no human clinical trials completed
- Anti-apoptotic properties raise theoretical concerns about promoting tumor cell survival
- No established human dosing or safety data
- Commercially available humanin peptides vary in purity and potency
Research Dosage References
- <strong>Intraperitoneal injection (animal studies)</strong> - 0.1-10 mg/kg (HNG analog) - Daily - No established human dosing. The S14G analog (HNG) is approximately 1000-fold more potent than native humanin in preclinical studies.
- <strong>Intracerebroventricular (animal studies)</strong> - 0.1-10 nmol - Single or repeated doses - Used in Alzheimer disease animal models for direct CNS delivery.
Mechanism of Action
Humanin exerts its cytoprotective effects through multiple signaling pathways. It binds to and activates a trimeric receptor complex consisting of CNTFR (ciliary neurotrophic factor receptor), WSX-1, and gp130 on the cell surface. Activation of this complex triggers JAK-STAT3 signaling, which upregulates anti-apoptotic gene expression and promotes cell survival. Humanin also interacts directly with intracellular pro-apoptotic proteins, including BAX (Bcl-2-associated X protein) and IGFBP-3 (insulin-like growth factor binding protein 3). By binding to BAX, humanin prevents BAX translocation to the mitochondrial membrane, blocking the intrinsic apoptotic cascade. Interaction with IGFBP-3 inhibits IGFBP-3-mediated apoptosis. Additionally, humanin has been shown to improve mitochondrial function, reduce reactive oxygen species (ROS) production, and enhance mitochondrial membrane potential in stressed cells. These effects may be mediated through direct interactions with mitochondrial complexes and regulation of mitochondrial dynamics. In the context of Alzheimer disease, humanin protects neurons from amyloid-beta toxicity through both receptor-mediated and intracellular mechanisms, reducing tau phosphorylation and promoting neuronal survival in preclinical models.
Legal Status
Not FDA approved. Not scheduled. Available as a research peptide.
Primary Sources
- Humanin, a peptide encoded by the mitochondrial genome, protects neuronal cells from amyloid-beta-induced toxicity. Journal of Neuroscience, 2001.
- The mitochondrial-derived peptide humanin as a therapeutic target in age-related diseases. Expert Opinion on Therapeutic Targets, 2017.
- Humanin levels in centenarians and their offspring: association with cardio-metabolic health. Aging Cell, 2009.